{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T11:32:46Z","timestamp":1774611166674,"version":"3.50.1"},"reference-count":104,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2015,4,1]],"date-time":"2015-04-01T00:00:00Z","timestamp":1427846400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2015,4,1]],"date-time":"2015-04-01T00:00:00Z","timestamp":1427846400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2015,4]]},"DOI":"10.1016\/j.clml.2014.09.012","type":"journal-article","created":{"date-parts":[[2014,10,5]],"date-time":"2014-10-05T16:04:26Z","timestamp":1412525066000},"page":"187-198","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":26,"title":["Optimizing the Treatment of Patients With\u00a0Multiple Myeloma and Renal Impairment"],"prefix":"10.1016","volume":"15","author":[{"given":"Norbert","family":"Grzasko","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marta","family":"Morawska","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marek","family":"Hus","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clml.2014.09.012_bib1","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1111\/j.1600-0609.1994.tb00190.x","article-title":"Renal function in newly diagnosed multiple myeloma\u2014a demographic study of 1353 patients. The Nordic Myeloma Study Group","volume":"53","author":"Knudsen","year":"1994","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.clml.2014.09.012_bib2","doi-asserted-by":"crossref","first-page":"9219","DOI":"10.1200\/JCO.2005.03.2086","article-title":"Early mortality after diagnosis of multiple myeloma: analysis of patients entered onto the United Kingdom Medical Research Council trials between 1980 and 2002\u2014Medical Research Council Adult Leukaemia Working Party","volume":"23","author":"Augustson","year":"2005","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2014.09.012_bib3","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1081\/JDI-100100888","article-title":"Renal involvement in multiple myeloma: a 10-year study","volume":"22","author":"Sakhuja","year":"2000","journal-title":"Ren Fail"},{"key":"10.1016\/j.clml.2014.09.012_bib4","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1111\/j.1365-2141.1995.tb05400.x","article-title":"Patients with multiple myeloma requiring long-term dialysis: presenting features, response to therapy, and outcome in a series of 20 cases","volume":"91","author":"Torra","year":"1995","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2014.09.012_bib5","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1038\/leu.2008.131","article-title":"Pathogenesis and treatment of renal failure in multiple myeloma","volume":"22","author":"Dimopoulos","year":"2008","journal-title":"Leukemia"},{"issue":"4 Pt 2","key":"10.1016\/j.clml.2014.09.012_bib6","first-page":"F521","article-title":"Receptor-mediated endocytosis of immunoglobulin light chains by renal proximal tubule cells","volume":"272","author":"Batuman","year":"1997","journal-title":"Am J Physiol"},{"key":"10.1016\/j.clml.2014.09.012_bib7","first-page":"659","article-title":"The ultrastructural basis of renal pathology in monoclonal gammopathies","volume":"18","author":"Santostefano","year":"2005","journal-title":"J\u00a0Nephrol"},{"key":"10.1016\/j.clml.2014.09.012_bib8","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1111\/j.1525-139X.2009.00582.x","article-title":"Free immunoglobulin light chains as a risk factor in renal and extrarenal complications","volume":"22","author":"Cohen","year":"2009","journal-title":"Semin Dial"},{"key":"10.1016\/j.clml.2014.09.012_bib9","doi-asserted-by":"crossref","first-page":"1977","DOI":"10.1046\/j.1523-1755.2002.00660.x","article-title":"Endocytosis of light chains induces cytokines through activation of NF-kappaB in human proximal tubule cells","volume":"62","author":"Sengul","year":"2002","journal-title":"Kidney Int"},{"key":"10.1016\/j.clml.2014.09.012_bib10","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1038\/ki.1987.286","article-title":"Human Bence Jones protein toxicity in rat proximal tubule epithelium in\u00a0vivo","volume":"32","author":"Sanders","year":"1987","journal-title":"Kidney Int"},{"key":"10.1016\/j.clml.2014.09.012_bib11","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1182\/blood-2010-03-258608","article-title":"Kidney disease associated with plasma cell dyscrasias","volume":"116","author":"Heher","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.clml.2014.09.012_bib12","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1034\/j.1600-0609.2000.90221.x","article-title":"Renal failure in multiple myeloma: reversibility and impact on the prognosis. Nordic Myeloma Study Group","volume":"65","author":"Knudsen","year":"2000","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.clml.2014.09.012_bib13","first-page":"2970","article-title":"Improvement in renal function in newly diagnosed myeloma improves survival, but still remains inferior to those with normal renal function","volume":"116","author":"Kumar","year":"2010","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"key":"10.1016\/j.clml.2014.09.012_bib14","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1111\/j.1600-0609.2009.01318.x","article-title":"Detection of renal impairment as one specific comorbidity factor in multiple myeloma: multicenter study in 198 consecutive patients","volume":"83","author":"Kleber","year":"2009","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.clml.2014.09.012_bib15","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1001\/archinte.1990.00040031693017","article-title":"Renal failure in multiple myeloma: pathogenesis and prognostic implications","volume":"150","author":"Alexanian","year":"1990","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.clml.2014.09.012_bib16","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1038\/sj.thj.6200003","article-title":"Are myeloma patients with renal failure candidates for autologous stem cell transplantation?","volume":"1","author":"San Miguel","year":"2000","journal-title":"Hematol J"},{"key":"10.1016\/j.clml.2014.09.012_bib17","doi-asserted-by":"crossref","first-page":"546","DOI":"10.3324\/haematol.10759","article-title":"Reversibility of renal failure in\u00a0newly diagnosed multiple myeloma patients treated with high dose dexamethasone-containing regimens and the impact of novel agents","volume":"92","author":"Kastritis","year":"2007","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2014.09.012_bib18","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1111\/j.1600-0609.2005.00446.x","article-title":"Autologous stem cell transplantation in multiple myeloma: outcome in patients with renal failure","volume":"75","author":"Knudsen","year":"2005","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.clml.2014.09.012_bib19","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1038\/leu.2008.402","article-title":"Improved survival of patients with multiple myeloma after the introduction of novel agents and the applicability of the International Staging System (ISS): an analysis of the Greek Myeloma Study Group (GMSG)","volume":"23","author":"Kastritis","year":"2009","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2014.09.012_bib20","doi-asserted-by":"crossref","first-page":"2516","DOI":"10.1182\/blood-2007-10-116129","article-title":"Improved survival in multiple myeloma and the impact of novel therapies","volume":"111","author":"Kumar","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.clml.2014.09.012_bib21","doi-asserted-by":"crossref","first-page":"2521","DOI":"10.1182\/blood-2007-08-104984","article-title":"Recent major improvement in long-term survival of younger patients with multiple myeloma","volume":"111","author":"Brenner","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.clml.2014.09.012_bib22","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1038\/leu.2008.325","article-title":"Treatment of newly diagnosed myeloma","volume":"23","author":"Palumbo","year":"2009","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2014.09.012_bib23","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1634\/theoncologist.12-6-664","article-title":"New drugs for myeloma","volume":"12","author":"Richardson","year":"2007","journal-title":"Oncologist"},{"key":"10.1016\/j.clml.2014.09.012_bib24","doi-asserted-by":"crossref","first-page":"149","DOI":"10.6004\/jnccn.2007.0015","article-title":"The emerging role of novel therapies for the treatment of relapsed myeloma","volume":"5","author":"Richardson","year":"2007","journal-title":"J\u00a0Natl Compr Canc Netw"},{"key":"10.1016\/j.clml.2014.09.012_bib25","first-page":"24","article-title":"New developments in the treatment of patients with multiple myeloma","volume":"68","author":"Minnema","year":"2010","journal-title":"Neth J Med"},{"key":"10.1016\/j.clml.2014.09.012_bib26","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1634\/theoncologist.2009-0203","article-title":"Current multiple myeloma treatment strategies with novel agents: a European perspective","volume":"15","author":"Ludwig","year":"2010","journal-title":"Oncologist"},{"key":"10.1016\/j.clml.2014.09.012_bib27","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1056\/NEJM199911183412102","article-title":"Antitumor activity of thalidomide in refractory multiple myeloma","volume":"341","author":"Singhal","year":"1999","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clml.2014.09.012_bib28","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1046\/j.1365-2141.2000.01835.x","article-title":"Therapy with thalidomide in refractory multiple myeloma patients\u2014the revival of an old drug","volume":"108","author":"Kneller","year":"2000","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2014.09.012_bib29","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1046\/j.1365-2141.2000.01983.x","article-title":"Frequent good partial remissions from thalidomide including best response ever in patients with advanced refractory and relapsed myeloma","volume":"109","author":"Juliusson","year":"2000","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2014.09.012_bib30","first-page":"408","article-title":"Salvage therapy with thalidomide in patients with advanced relapsed\/refractory multiple myeloma","volume":"87","author":"Tosi","year":"2002","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2014.09.012_bib31","doi-asserted-by":"crossref","first-page":"4459","DOI":"10.1200\/JCO.2007.12.3463","article-title":"Melphalan, prednisone, and lenalidomide treatment for newly diagnosed myeloma: a report from the GIMEMA\u2014Italian Multiple Myeloma Network","volume":"25","author":"Palumbo","year":"2007","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2014.09.012_bib32","first-page":"826","article-title":"First-line therapy with thalidomide and dexamethasone in preparation for autologous stem cell transplantation for multiple myeloma","volume":"89","author":"Cavo","year":"2004","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2014.09.012_bib33","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1038\/sj.bmt.1705050","article-title":"First-line thalidomide-dexamethasone therapy in preparation for autologous stem cell transplantation in young patients (<61 years) with symptomatic multiple myeloma","volume":"36","author":"Abdelkefi","year":"2005","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.clml.2014.09.012_bib34","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1016\/j.leukres.2010.05.003","article-title":"The efficacy and safety of the low-thalidomide dose CTD (cyclophosphamide, thalidomide, dexamethasone) regimen in patients with multiple myeloma\u2014a report by the Polish Myeloma Study Group","volume":"34","author":"Dmoszynska","year":"2010","journal-title":"Leuk Res"},{"key":"10.1016\/j.clml.2014.09.012_bib35","first-page":"295","article-title":"Analysis of plasma concentration of thalidomide in Japanese patients of multiple myeloma with renal dysfunction","volume":"50","author":"Arai","year":"2009","journal-title":"Rinsho Ketsueki"},{"key":"10.1016\/j.clml.2014.09.012_bib36","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.1211\/0022357022241","article-title":"Pharmacokinetics of thalidomide in patients with impaired renal function and while on and off dialysis","volume":"55","author":"Eriksson","year":"2003","journal-title":"J\u00a0Pharm Pharmacol"},{"key":"10.1016\/j.clml.2014.09.012_bib37","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1080\/10428190310001638841","article-title":"Aminoglycoside-associated severe renal failure in patients with multiple myeloma treated with thalidomide","volume":"45","author":"Montagut","year":"2004","journal-title":"Leuk Lymphoma"},{"issue":"suppl","key":"10.1016\/j.clml.2014.09.012_bib38","doi-asserted-by":"crossref","first-page":"e13093","DOI":"10.1200\/jco.2010.28.15_suppl.e13093","article-title":"Treatment for patients with multiple myeloma complicated by renal failure by thalidomide-based regimens. [Abstract from 2010 ASCO Annual Meeting]","volume":"28","author":"Seol","year":"2010","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2014.09.012_bib39","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1111\/j.1600-0609.2004.00272.x","article-title":"Thalidomide alone or in combination with dexamethasone in patients with advanced, relapsed or refractory multiple myeloma and renal failure","volume":"73","author":"Tosi","year":"2004","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.clml.2014.09.012_bib40","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1046\/j.1365-2141.2003.04395_2.x","article-title":"Use of thalidomide in patients with myeloma and renal failure may be associated with unexplained hyperkalaemia","volume":"122","author":"Harris","year":"2003","journal-title":"Br\u00a0J Haematol"},{"key":"10.1016\/j.clml.2014.09.012_bib41","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1111\/j.1365-2141.2004.04875.x","article-title":"Thalidomide in patients with multiple myeloma and renal failure","volume":"125","author":"Fakhouri","year":"2004","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2014.09.012_bib42","doi-asserted-by":"crossref","first-page":"605","DOI":"10.2169\/internalmedicine.42.605","article-title":"Thalidomide treatment for immunoglobulin D multiple myeloma in a patient on chronic hemodialysis","volume":"42","author":"Hayashi","year":"2003","journal-title":"Intern Med"},{"key":"10.1016\/j.clml.2014.09.012_bib43","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1016\/j.bbmt.2010.02.020","article-title":"Thalidomide-dexamethasone as induction therapy before autologous stem cell transplantation in patients with newly diagnosed multiple myeloma and renal insufficiency","volume":"16","author":"Tosi","year":"2010","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.clml.2014.09.012_bib44","doi-asserted-by":"crossref","first-page":"241","DOI":"10.3816\/CLM.2003.n.005","article-title":"Tolerability and efficacy of thalidomide for the treatment of patients with light chain-associated (AL) amyloidosis","volume":"3","author":"Seldin","year":"2003","journal-title":"Clin Lymphoma"},{"key":"10.1016\/j.clml.2014.09.012_bib45","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1056\/NEJMoa070594","article-title":"Multiple Myeloma (010) Study Investigators. Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma","volume":"357","author":"Dimopoulos","year":"2007","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clml.2014.09.012_bib46","doi-asserted-by":"crossref","first-page":"2133","DOI":"10.1056\/NEJMoa070596","article-title":"Multiple Myeloma (009) Study Investigators. Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America","volume":"357","author":"Weber","year":"2007","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clml.2014.09.012_bib47","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.3109\/10428191003721342","article-title":"Single agent lenalidomide in newly diagnosed multiple myeloma: a retrospective analysis","volume":"51","author":"Baz","year":"2010","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.clml.2014.09.012_bib48","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S1470-2045(09)70284-0","article-title":"Eastern Cooperative Oncology Group. Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial","volume":"11","author":"Rajkumar","year":"2010","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clml.2014.09.012_bib49","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1002\/ajh.22053","article-title":"Lenalidomide, cyclophosphamide and dexamethasone (CRd) for newly diagnosed multiple myeloma: results from a phase 2 trial","volume":"86","author":"Kumar","year":"2011","journal-title":"Am J Hematol"},{"key":"10.1016\/j.clml.2014.09.012_bib50","doi-asserted-by":"crossref","first-page":"1466","DOI":"10.1177\/0091270007309563","article-title":"Pharmacokinetics of lenalidomide in subjects with various degrees of renal impairment and in subjects on hemodialysis","volume":"47","author":"Chen","year":"2007","journal-title":"J\u00a0Clin Pharmacol"},{"key":"10.1016\/j.clml.2014.09.012_bib51","doi-asserted-by":"crossref","first-page":"3807","DOI":"10.1002\/cncr.25139","article-title":"The efficacy and safety of lenalidomide plus dexamethasone in relapsed and\/or refractory multiple myeloma patients with impaired renal function","volume":"116","author":"Dimopoulos","year":"2010","journal-title":"Cancer"},{"key":"10.1016\/j.clml.2014.09.012_bib52","article-title":"Use of lenalidomide may surmount the adverse prognosis induced by renal impairment in patients (pts) with relapsed\/refractory multiple myeloma (MM)","volume":"116","author":"Kleber","year":"2010","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"key":"10.1016\/j.clml.2014.09.012_bib53","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1007\/s00277-010-1080-4","article-title":"Lenalidomide in combination with dexamethasone: effective regimen in patients with relapsed or refractory multiple myeloma complicated by renal impairment","volume":"90","author":"Klein","year":"2011","journal-title":"Ann Hematol"},{"key":"10.1016\/j.clml.2014.09.012_bib54","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1111\/j.1600-0609.2010.01500.x","article-title":"Activity and safety of lenalidomide and dexamethasone in patients with multiple myeloma requiring dialysis: a Spanish multicenter retrospective study","volume":"85","author":"de la Rubia","year":"2010","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.clml.2014.09.012_bib55","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1111\/j.1365-2141.2007.06698.x","article-title":"Lenalidomide-induced myelosuppression is associated with renal dysfunction: adverse events evaluation of treatment-na\u00efve patients undergoing front-line lenalidomide and dexamethasone therapy","volume":"138","author":"Niesvizky","year":"2007","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2014.09.012_bib56","article-title":"Use of lenalidomide (Revlimid(R))\u00a0+\/- corticosteroids in relapsed\/refractory multiple myeloma patients with elevated baseline serum creatinine levels","volume":"108","author":"Reece","year":"2006","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"key":"10.1016\/j.clml.2014.09.012_bib57","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1600-0609.2010.01432.x","article-title":"Lenalidomide and dexamethasone for the treatment of refractory\/relapsed multiple myeloma: dosing of lenalidomide according to renal function and effect on renal impairment","volume":"85","author":"Dimopoulos","year":"2010","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.clml.2014.09.012_bib58","article-title":"Lower-dose lenalidomide and dexamethasone reduces toxicity without compromising efficacy in patients with relapsed\/refractory myeloma, who are aged\u00a0\u226560 years or have renal impairment: planned interim results of a prospective multicentre phase II trial","volume":"116","author":"Quach","year":"2010","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"key":"10.1016\/j.clml.2014.09.012_bib59","volume":"108","author":"Weber","year":"2006","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"key":"10.1016\/j.clml.2014.09.012_bib60","doi-asserted-by":"crossref","first-page":"5008","DOI":"10.1200\/JCO.2009.23.6802","article-title":"Pomalidomide (CC4047) plus low-dose dexamethasone as therapy for relapsed multiple myeloma","volume":"27","author":"Lacy","year":"2009","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2014.09.012_bib61","doi-asserted-by":"crossref","first-page":"2487","DOI":"10.1056\/NEJMoa043445","article-title":"Assessment of Proteasome Inhibition for Extending Remissions (APEX) Investigators. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma","volume":"352","author":"Richardson","year":"2005","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clml.2014.09.012_bib62","doi-asserted-by":"crossref","first-page":"3557","DOI":"10.1182\/blood-2006-08-036947","article-title":"Extended follow-up of a phase 3 trial in relapsed multiple myeloma: final time-to-event results of the APEX trial","volume":"110","author":"Richardson","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.clml.2014.09.012_bib63","doi-asserted-by":"crossref","first-page":"2946","DOI":"10.1200\/JCO.2011.39.6820","article-title":"Bortezomib induction and maintenance treatment in patients with newly diagnosed multiple myeloma: results of the randomized phase III HOVON-65\/GMMG-HD4 trial","volume":"30","author":"Sonneveld","year":"2012","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2014.09.012_bib64","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1056\/NEJMoa0801479","article-title":"VISTA Trial Investigators. Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma","volume":"359","author":"San Miguel","year":"2008","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clml.2014.09.012_bib65","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1200\/JCO.2012.41.6180","article-title":"Persistent overall survival benefit and no increased risk of second malignancies with bortezomib-melphalan-prednisone versus melphalan-prednisone in patients with previously untreated multiple myeloma","volume":"31","author":"San Miguel","year":"2013","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2014.09.012_bib66","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1124\/jpet.108.142604","article-title":"Bortezomib-induced survival signals and genes in human proximal tubular cells","volume":"327","author":"Sark\u00f6zi","year":"2008","journal-title":"J\u00a0Pharmacol Exp Ther"},{"key":"10.1016\/j.clml.2014.09.012_bib67","doi-asserted-by":"crossref","first-page":"372","DOI":"10.3324\/haematol.2008.000638","article-title":"Cystatin-C is an independent prognostic factor for survival in multiple myeloma and is reduced by bortezomib administration","volume":"94","author":"Terpos","year":"2009","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2014.09.012_bib68","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1007\/s00280-011-1637-5","article-title":"Dose-escalating and pharmacological study of bortezomib in adult cancer patients with impaired renal function: a National Cancer Institute Organ Dysfunction Working Group Study","volume":"68","author":"Leal","year":"2011","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.clml.2014.09.012_bib69","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1021\/tx050313d","article-title":"Oxidative deboronation of the peptide boronic acid proteasome inhibitor bortezomib: contributions from reactive oxygen species in this novel cytochrome P450 reaction","volume":"19","author":"Labutti","year":"2006","journal-title":"Chem Res Toxicol"},{"key":"10.1016\/j.clml.2014.09.012_bib70","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1124\/dmd.105.005710","article-title":"Relative contributions of the five major human cytochromes P450, 1A2, 2C9, 2C19, 2D6, and 3A4, to the hepatic metabolism of the proteasome inhibitor bortezomib","volume":"33","author":"Uttamsingh","year":"2005","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.clml.2014.09.012_bib71","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1124\/dmd.104.002956","article-title":"Human metabolism of the proteasome inhibitor bortezomib: identification of circulating metabolites","volume":"33","author":"Pekol","year":"2005","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.clml.2014.09.012_bib72","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1038\/sj.leu.2405087","article-title":"Efficacy and safety of bortezomib in patients with renal impairment: results from the APEX phase 3 study","volume":"22","author":"San Miguel","year":"2008","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2014.09.012_bib73","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1002\/cncr.20888","article-title":"SUMMIT\/CREST Investigators. Bortezomib in recurrent and\/or refractory multiple myeloma: initial clinical experience in patients with impaired renal function","volume":"103","author":"Jagannath","year":"2005","journal-title":"Cancer"},{"key":"10.1016\/j.clml.2014.09.012_bib74","article-title":"Renal dysfunction does not affect clinical response in multiple myeloma (MM) patients treated with bortezomib-based regimens","volume":"110","author":"Ailawadhi","year":"2007","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"key":"10.1016\/j.clml.2014.09.012_bib75","doi-asserted-by":"crossref","first-page":"6086","DOI":"10.1200\/JCO.2009.22.2232","article-title":"VMP (bortezomib, melphalan, and prednisone) is active and well tolerated in newly diagnosed patients with multiple myeloma with moderately impaired renal function, and results in reversal of renal impairment: cohort analysis of the phase III VISTA study","volume":"27","author":"Dimopoulos","year":"2009","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2014.09.012_bib76","doi-asserted-by":"crossref","first-page":"2604","DOI":"10.1182\/blood-2006-09-046409","article-title":"Activity and safety of bortezomib in multiple myeloma patients with advanced renal failure: a multicenter retrospective study","volume":"109","author":"Chanan-Khan","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.clml.2014.09.012_bib77","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1111\/j.1600-0609.2009.01385.x","article-title":"Safety and efficacy of bortezomib-based regimens for multiple myeloma patients with renal impairment: a retrospective study of Italian Myeloma Network GIMEMA","volume":"84","author":"Morabito","year":"2010","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.clml.2014.09.012_bib78","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1080\/10428190801930506","article-title":"Treatment of patients with multiple myeloma complicated by renal failure with bortezomib-based regimens","volume":"49","author":"Roussou","year":"2008","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.clml.2014.09.012_bib79","doi-asserted-by":"crossref","first-page":"4635","DOI":"10.1200\/JCO.2010.28.1238","article-title":"Light chain-induced acute renal failure can be reversed by bortezomib-doxorubicin-dexamethasone in multiple myeloma: results of a phase II study","volume":"28","author":"Ludwig","year":"2010","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2014.09.012_bib80","doi-asserted-by":"crossref","first-page":"394","DOI":"10.3816\/CLM.2009.n.077","article-title":"Bortezomib and dexamethasone therapy for newly diagnosed patients with multiple myeloma complicated by renal impairment","volume":"9","author":"Li","year":"2009","journal-title":"Clin Lymphoma Myeloma"},{"key":"10.1016\/j.clml.2014.09.012_bib81","doi-asserted-by":"crossref","first-page":"5661","DOI":"10.1182\/blood-2012-03-414359","article-title":"An open-label, single-arm, phase 2 (PX-171-004) study of single-agent carfilzomib in bortezomib-naive patients with relapsed and\/or refractory multiple myeloma","volume":"119","author":"Vij","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.clml.2014.09.012_bib82","doi-asserted-by":"crossref","first-page":"2817","DOI":"10.1182\/blood-2012-05-425934","article-title":"A\u00a0phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma","volume":"120","author":"Siegel","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.clml.2014.09.012_bib83","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1111\/j.1365-2141.2012.09232.x","article-title":"An open-label, single-arm, phase 2 study of single-agent carfilzomib in patients with relapsed and\/or refractory multiple myeloma who have been previously treated with bortezomib","volume":"158","author":"Vij","year":"2012","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2014.09.012_bib84","doi-asserted-by":"crossref","first-page":"1707","DOI":"10.1038\/leu.2013.29","article-title":"Carfilzomib in multiple myeloma patients with renal impairment: pharmacokinetics and safety","volume":"27","author":"Badros","year":"2013","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2014.09.012_bib85","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1046\/j.1365-2141.2001.03033.x","article-title":"Results of autologous stem cell transplant in multiple myeloma patients with renal failure","volume":"114","author":"Badros","year":"2001","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2014.09.012_bib86","first-page":"3091","article-title":"Autologous stem cell transplantation for multiple myeloma in patients with reduced renal function: a matched set comparison","volume":"108","author":"Kumar","year":"2006","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"key":"10.1016\/j.clml.2014.09.012_bib87","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1111\/j.1365-2141.2006.06191.x","volume":"134","author":"Bird","year":"2006","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2014.09.012_bib88","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1038\/sj.bmt.1704948","article-title":"Melphalan 200 mg\/m2 with blood stem cell support as first-line myeloma therapy: impact of glomerular filtration rate on engraftment, transplantation-related toxicity and survival","volume":"35","author":"Carlson","year":"2005","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.clml.2014.09.012_bib89","article-title":"Bendamustine in patients with renal insufficiency","volume":"26","author":"Preiss","year":"2003","journal-title":"Onkologie"},{"key":"10.1016\/j.clml.2014.09.012_bib90","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1007\/s00432-012-1212-4","article-title":"Successful treatment of patients with newly diagnosed\/untreated multiple myeloma and advanced renal failure using bortezomib in combination with bendamustine and prednisone","volume":"138","author":"P\u00f6nisch","year":"2012","journal-title":"J\u00a0Cancer Res Clin Oncol"},{"key":"10.1016\/j.clml.2014.09.012_bib91","doi-asserted-by":"crossref","first-page":"1937","DOI":"10.1007\/s00432-013-1513-2","article-title":"Bendamustine and prednisone in combination with bortezomib (BPV) in the treatment of patients with relapsed or refractory multiple myeloma and light chain-induced renal failure","volume":"139","author":"P\u00f6nisch","year":"2013","journal-title":"J\u00a0Cancer Res Clin Oncol"},{"key":"10.1016\/j.clml.2014.09.012_bib92","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1111\/j.1365-2141.2011.08754.x","article-title":"Bendamustine in combination with thalidomide and dexamethasone is an effective therapy for myeloma patients with end stage renal disease","volume":"155","author":"Ramasamy","year":"2011","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2014.09.012_bib93","doi-asserted-by":"crossref","first-page":"777","DOI":"10.7326\/0003-4819-143-11-200512060-00005","article-title":"Canadian Apheresis Group. Plasma exchange when myeloma presents as acute renal failure: a randomized, controlled trial","volume":"143","author":"Clark","year":"2005","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.clml.2014.09.012_bib94","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1681\/ASN.2006080821","article-title":"Efficient removal of immunoglobulin free light chains by hemodialysis for multiple myeloma: in\u00a0vitro and in\u00a0vivo studies","volume":"18","author":"Hutchison","year":"2007","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.clml.2014.09.012_bib95","doi-asserted-by":"crossref","first-page":"745","DOI":"10.2215\/CJN.04590908","article-title":"Treatment of acute renal failure secondary to multiple myeloma with chemotherapy and extended high cut-off hemodialysis","volume":"4","author":"Hutchison","year":"2009","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.clml.2014.09.012_bib96","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1681\/ASN.2010080857","article-title":"Early reduction of serum-free light chains associates with renal recovery in myeloma kidney","volume":"22","author":"Hutchison","year":"2011","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.clml.2014.09.012_bib97","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1111\/j.1744-9987.2010.00863.x","article-title":"Evaluation of blood purification and bortezomib plus dexamethasone therapy for the treatment of acute renal failure due to myeloma cast nephropathy","volume":"14","author":"Hasegawa","year":"2010","journal-title":"Ther Apher Dial"},{"key":"10.1016\/j.clml.2014.09.012_bib98","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1038\/ki.2008.108","article-title":"Improvement of cast nephropathy with plasma exchange depends on the diagnosis and on reduction of serum free light chains","volume":"73","author":"Leung","year":"2008","journal-title":"Kidney Int"},{"key":"10.1016\/j.clml.2014.09.012_bib99","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1093\/annonc\/mdn796","article-title":"The use of bisphosphonates in multiple myeloma: recommendations of an expert panel on behalf of the European Myeloma Network","volume":"20","author":"Terpos","year":"2009","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clml.2014.09.012_bib100","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1038\/leu.2013.350","article-title":"New drugs and novel mechanisms of action in multiple myeloma in 2013: a report from the International Myeloma Working Group (IMWG)","volume":"28","author":"Ocio","year":"2014","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2014.09.012_bib101","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1182\/blood-2014-01-548826","article-title":"Phase 1 study of twice-weekly ixazomib, an oral proteasome inhibitor, in relapsed\/refractory multiple myeloma patients","volume":"124","author":"Richardson","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.clml.2014.09.012_bib102","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1681\/ASN.2012060590","article-title":"Renoprotective effect of combined inhibition of angiotensin-converting enzyme and histone deacetylase","volume":"24","author":"Zhong","year":"2013","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.clml.2014.09.012_bib103","doi-asserted-by":"crossref","first-page":"2205","DOI":"10.1016\/j.ajpath.2011.01.044","article-title":"Long-term administration of the histone deacetylase inhibitor vorinostat attenuates renal injury in experimental diabetes through an endothelial nitric oxide synthase-dependent mechanism","volume":"178","author":"Advani","year":"2011","journal-title":"Am J Pathol"},{"key":"10.1016\/j.clml.2014.09.012_bib104","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1007\/s00280-012-1940-9","article-title":"Characterizing the disposition, metabolism, and excretion of an orally active pan-deacetylase inhibitor, panobinostat, via trace radiolabeled 14C material in advanced cancer patients","volume":"70","author":"Clive","year":"2012","journal-title":"Cancer Chemother Pharmacol"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265014004224?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265014004224?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:26:04Z","timestamp":1761870364000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265014004224"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,4]]},"references-count":104,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2015,4]]}},"alternative-id":["S2152265014004224"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2014.09.012","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2015,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Optimizing the Treatment of Patients With\u00a0Multiple Myeloma and Renal Impairment","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2014.09.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}